ClinicalTrials.gg
CompletedNCT04492020UBR ProdromeUpdated May 31, 2023Results posted

Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants

A Phase 3 interventional study of Ubrogepant 100 mg and Placebo in Migraine, sponsored by AbbVie. Completed at 73 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-31.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
518
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing ubrogepant in Migraine Disorders — 2 open to participants now, 4 under way, 3 of them phase 3. ubrogepant · Migraine Disorders.

Enrollment
7th of 14
518 · median 507
Started
2020
the only one that year
Phase 3
7 of 14
2 open now
Registered
7th of 14
by date
Lead sponsor
6 of 14
AbbVie

Among the 14 studies testing ubrogepant in Migraine Disorders, this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 7 in phase 3, and was the 7th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

2 of the 14 studies testing ubrogepant in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About ubrogepant

ubrogepant: first FDA approval 2019 (UBRELVY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ubrogepant in Migraine Disorders, or all of them as a file.
02

Study summary

Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • Migraine
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least a 1-year history of migraine with or without aura consistent with a diagnosis according to the ICHD-3 (International Classification of Headache Disorders 3rd edition)
  • Migraine onset before age 50 years
  • By history, the participant's migraines typically last between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom
  • History of 2 to 8 migraine attacks per month with moderate to severe headache in each of the 3 months prior to the Screening Visit

Exclusion criteria

Exclusion Criteria:

  • Difficulty distinguishing migraine headache from tension-type or other headaches
  • Participants who overuse medication for migraine defined as use of opioids or barbiturates > 2 days/month, triptans or ergots ≥ 10 days/month, or simple analgesics (eg, aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen) ≥ 15 days/month in the 3 months prior to Visit 1 per investigator's judgment
  • Has a history of migraine aura with diplopia or impairment of level of consciousness, hemiplegic migraine, or retinal migraine as defined by ICHD-3
  • A current diagnosis of chronic migraine as defined by ICHD-3 or a history of 15 or more headache days per month on average in the 6 months prior to Visit 1 in the investigator's judgment. A headache day is defined as a day in which there was any occurrence of a headache of a minimum duration of 2 hours or a headache of any duration for which acute medication was taken
  • Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3
  • Required hospital treatment of a migraine attack 3 or more times in the 6 months prior to Visit 1
  • History of in the 5 years prior to Visit 1, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
  • History of any prior gastrointestinal conditions (eg, diarrhea syndromes, inflammatory bowel disease) that, per investigator judgment, may affect the absorption or metabolism of the study intervention; participants with prior gastric bariatric interventions (eg, Lap Band) which have been reversed are not excluded
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
518 participants (actual)

Study arms

  • Experimental
    Treatment Sequence A

    Participants randomized to Treatment Sequence A will receive placebo to treat their first qualifying prodrome event and ubrogepant 100 mg to treat their second qualifying prodrome event

    Drug: Ubrogepant 100 mg · Drug: Placebo

  • Experimental
    Treatment Sequence B

    Participants randomized to Treatment Sequence B will receive ubrogepant 100 mg to treat their first qualifying prodrome event and placebo to treat their second qualifying prodrome event

    Drug: Ubrogepant 100 mg · Drug: Placebo

Interventions

  • For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours

  • DrugPlacebo

    For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose

    The absence of a headache of moderate/severe intensity will be recorded by the participant in an electronic diary (eDiary) within 24 hours after taking double-blind study intervention during the prodrome in order to determine the attenuation of headache. The absence of moderate or severe headache are derived based on headache record and rescue use.

    Time frame: 24 hours after taking double-blind study intervention during the prodrome

Secondary outcomes

  1. Percentage of Participants Reporting Absence of Headache of Moderate or Severe Intensity Within 48 Hours Post-dose

    The absence of a headache of moderate or severe intensity will be recorded by the participant in an eDiary within 48 hours after taking double-blind study intervention during the prodrome in order to determine the prevention of headache

    Time frame: 48 hours after taking double-blind study intervention during the prodrome

  2. Percentage of Participants Reporting Improvement in the Ability to Function Normally Over 24 Hours Post-dose

    The Functional Disability Scale (FDS) is a single item used to measure the participant's level to function normally. Participants will be asked to rate the performance of daily activities using 4 response options ranging from 0 (no disability, able to function normally) to 3 (severely impaired, cannot do all or most things, bed rest may be necessary) within 24 hours after taking double-blind study intervention during the prodrome

    Time frame: 24 hours after taking double-blind study intervention during the prodrome

  3. Percentage of Participants Reporting Absence of Headache of Any Intensity Within 24 Hours Post-dose

    The absence of a headache of moderate/severe intensity will be recorded by the participant in an electronic diary (eDiary) within 24 hours after taking double-blind study intervention during the prodrome in order to determine the attenuation of headache. The absence of moderate or severe headache are derived based on headache record and rescue use.

    Time frame: 24 hours after taking double-blind study intervention during the prodrome

07

Results

Posted May 31, 2023

Participant flow

Participant flow — Overall Study
MilestoneTreatment Sequence ATreatment Sequence B
Started264254
Safety population247233
Completed223215
Not completed4139
Withdrew: Adverse event13
Withdrew: Withdrawal by subject43
Withdrew: Lost to follow-up43
Withdrew: Protocol violation52
Withdrew: Lack of qualifying event2527
Withdrew: Non-compliance with study drug21

Outcome measures

PrimaryPercentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose

The absence of a headache of moderate/severe intensity will be recorded by the participant in an electronic diary (eDiary) within 24 hours after taking double-blind study intervention during the prodrome in order to determine the attenuation of headache. The absence of moderate or severe headache are derived based on headache record and rescue use.

Time frame:
24 hours after taking double-blind study intervention during the prodrome
Reported as:
Count of participants · Participants
Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose
ParticipantsPlaceboUbrogepant 100 mg
Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose121190
Statistical analysis
  • Ubrogepant 100 mg · generalized linear mixed model (GLMM) · p = <.0001 · Odds ratio (or): 2.09 · 95% CI 1.63 to 2.69
SecondaryPercentage of Participants Reporting Absence of Headache of Moderate or Severe Intensity Within 48 Hours Post-dose

The absence of a headache of moderate or severe intensity will be recorded by the participant in an eDiary within 48 hours after taking double-blind study intervention during the prodrome in order to determine the prevention of headache

Time frame:
48 hours after taking double-blind study intervention during the prodrome
Reported as:
Count of participants · Participants
Percentage of Participants Reporting Absence of Headache of Moderate or Severe Intensity Within 48 Hours Post-dose
ParticipantsPlaceboUbrogepant 100 mg
Percentage of Participants Reporting Absence of Headache of Moderate or Severe Intensity Within 48 Hours Post-dose100159
Statistical analysis
  • Ubrogepant 100 mg · generalized linear mixed model (GLMM) · p = <.0001 · Odds ratio (or): 2.13 · 95% CI 1.63 to 2.78
SecondaryPercentage of Participants Reporting Improvement in the Ability to Function Normally Over 24 Hours Post-dose

The Functional Disability Scale (FDS) is a single item used to measure the participant's level to function normally. Participants will be asked to rate the performance of daily activities using 4 response options ranging from 0 (no disability, able to function normally) to 3 (severely impaired, cannot do all or most things, bed rest may be necessary) within 24 hours after taking double-blind study intervention during the prodrome

Time frame:
24 hours after taking double-blind study intervention during the prodrome
Reported as:
Count of participants · Participants
Percentage of Participants Reporting Improvement in the Ability to Function Normally Over 24 Hours Post-dose
ParticipantsPlaceboUbrogepant 100 mg
1 Hour — Responder96107
1 Hour — Nonresponder336311
2 Hours — Responder110156
2 Hours — Nonresponder311266
3 Hours — Responder150199
3 Hours — Nonresponder269213
4 Hours — Responder173245
4 Hours — Nonresponder244170
6 Hours — Responder210266
6 Hours — Nonresponder190129
8 Hours — Responder239291
8 Hours — Nonresponder15597
24 Hours — Responder342367
24 Hours — Nonresponder6246
Statistical analysis
  • Placebo · generalized estimating equation (GEE) · p = <.0001 · Geometric mean odds ratio: 1.66 · 95% CI 1.40 to 1.96
SecondaryPercentage of Participants Reporting Absence of Headache of Any Intensity Within 24 Hours Post-dose

The absence of a headache of moderate/severe intensity will be recorded by the participant in an electronic diary (eDiary) within 24 hours after taking double-blind study intervention during the prodrome in order to determine the attenuation of headache. The absence of moderate or severe headache are derived based on headache record and rescue use.

Time frame:
24 hours after taking double-blind study intervention during the prodrome
Reported as:
Count of participants · Participants
Percentage of Participants Reporting Absence of Headache of Any Intensity Within 24 Hours Post-dose
ParticipantsPlaceboUbrogepant 100 mg
Percentage of Participants Reporting Absence of Headache of Any Intensity Within 24 Hours Post-dose61103
Statistical analysis
  • Ubrogepant 100 mg · generalized linear mixed model (GLMM) · p = <.0001 · Odds ratio (or): 1.93 · 95% CI 1.39 to 2.66

Adverse events

Collected over From first dose through 30 days after the last dose of study drug (approximately 30 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/462 (0%)1/462 (0.2%)35/462 (7.6%)
Ubrogepant 100 mg0/456 (0%)0/456 (0%)50/456 (11%)
Most frequent serious events
Most frequent serious events
EventPlaceboUbrogepant 100 mg
RHABDOMYOLYSISMusculoskeletal and connective tissue disorders1/4620/456
Most frequent other events
Most frequent other events
EventPlaceboUbrogepant 100 mg
NAUSEAGastrointestinal disorders17/46224/456
DIZZINESSNervous system disorders14/46211/456
FATIGUEGeneral disorders7/46212/456
SOMNOLENCENervous system disorders5/46211/456

Baseline characteristics

Safety Population consists of all treated participants who take at least 1 administration of study intervention

Age, Continuous
Age, Continuous(years)Treatment Sequence ATreatment Sequence BTotal
Mean41.7 ± 12.6342.9 ± 13.1042.3 ± 12.86
Age, Customized
Age, Customized(Participants)Treatment Sequence ATreatment Sequence BTotal
< 20527
20 - 29423880
30 - 396260122
40 - 496864132
50 - 59483785
60 - 69182846
>= 70448
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence ATreatment Sequence BTotal
Female216205421
Male312859
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Sequence ATreatment Sequence BTotal
Hispanic or Latino171532
Not Hispanic or Latino229216445
Unknown or Not Reported123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Sequence ATreatment Sequence BTotal
American Indian or Alaska Native000
Asian7411
Native Hawaiian or Other Pacific Islander112
Black or African American221537
White214209423
More than one race246
Unknown or Not Reported101
08

Study locations

73 sites
  • Achieve Clinical Research, LLC /ID# 237098
    Birmingham, Alabama 35216, United States
  • Barrow Neuro Institute /ID# 236775
    Phoenix, Arizona 85013, United States
  • Arkansas Clinical Research /ID# 238032
    Little Rock, Arkansas 72205, United States
  • California Headache and Balance Center /ID# 236247
    Fresno, California 93720, United States
  • Sun Valley Research Center /ID# 236561
    Imperial, California 92251-9401, United States
  • Wr-Pri Llc /Id# 236007
    Los Alamitos, California 90720, United States
  • Pharmacology Research Institute (PRI) - Newport Beach (Wake) /ID# 237691
    Newport Beach, California 92660, United States
  • Excell Research, Inc /ID# 237721
    Oceanside, California 92056, United States
  • George J. Rederich M.D. Inc. /ID# 235769
    Torrance, California 90505, United States
  • Diablo Clinical Research /ID# 237570
    Walnut Creek, California 94598, United States
  • Colorado Springs Neurological Associates (CSNA) /ID# 236556
    Colorado Springs, Colorado 80907, United States
  • Advanced Neurosciences Research, LLC /ID# 237426
    Fort Collins, Colorado 80528, United States
  • CNS Healthcare - Jacksonville /ID# 238245
    Jacksonville, Florida 32256-6039, United States
  • Health Awareness, Inc - Jupiter /ID# 236226
    Jupiter, Florida 33458-7021, United States
  • Suncoast Clinical Research /ID# 236934
    New Port Richey, Florida 34652, United States
  • Sensible Healthcare /ID# 238090
    Ocoee, Florida 34761, United States
  • Clinical Neuroscience Solutions, Inc /ID# 236608
    Orlando, Florida 32801-2986, United States
  • Accel Research Sites - St Petersburg Clinical Research Unit /ID# 237163
    Saint Petersburg, Florida 33709-3113, United States
  • University of South Florida /ID# 234387
    Tampa, Florida 33606, United States
  • ForCare Clinical Research /ID# 237092
    Tampa, Florida 33613-1244, United States
  • Premiere Research Institute - Palm Beach /ID# 238193
    West Palm Beach, Florida 33407-3209, United States
  • NeuroTrials Research Inc. /ID# 237365
    Atlanta, Georgia 30328, United States
  • iResearch Atlanta, LLC /ID# 237390
    Decatur, Georgia 30030, United States
  • Meridian Clinical Research (Neurology) - Savannah /ID# 234371
    Savannah, Georgia 31406-2758, United States
  • Clinical Research Atlanta - Headlands LLC /ID# 234438
    Stockbridge, Georgia 30281-9054, United States
  • Northwest Clinical Trials /ID# 234968
    Boise, Idaho 83704, United States
  • Deaconess Clinic Downtown /ID# 236959
    Evansville, Indiana 47713-1227, United States
  • PMG Research of McFarland /ID# 238271
    Ames, Iowa 50010-5733, United States
  • Collective Medical Research /ID# 236402
    Overland Park, Kansas 66210, United States
  • Kansas Institute of Research /ID# 236738
    Overland Park, Kansas 66211-1363, United States
  • Boston Clinical Trials /ID# 236559
    Boston, Massachusetts 02131-2515, United States
  • Michigan Headache & Neurological Institute (MHNI) /ID# 236565
    Ann Arbor, Michigan 48104-5131, United States
  • Minneapolis Clinic of Neurology - Golden Valley /ID# 238162
    Golden Valley, Minnesota 55422-4215, United States
  • Clinical Research Institute, Inc /ID# 238301
    Minneapolis, Minnesota 55402-2606, United States
  • StudyMetrix Research /ID# 236457
    Saint Peters, Missouri 63303, United States
  • Clinvest Research LLC /ID# 237908
    Springfield, Missouri 65807, United States
  • Princeton Center for Clinical Research /ID# 235734
    Skillman, New Jersey 08558, United States
  • Bio Behavioral Health, Inc /ID# 238212
    Toms River, New Jersey 08755-6434, United States
  • Dent Neurosciences Research Center, Inc. /ID# 237039
    Amherst, New York 14226, United States
  • Central New York Clinical Research /ID# 235694
    Manlius, New York 13104, United States
  • Rochester Clinical Research /ID# 236842
    New York, New York 14609, United States
  • Upstate Clinical Research Associates /ID# 238220
    Williamsville, New York 14221-6046, United States
  • PMG Research of Charlotte /ID# 237048
    Charlotte, North Carolina 28209, United States
  • Raleigh Neurology Associates /ID# 237138
    Raleigh, North Carolina 27607, United States
  • CTI Clinical Research Center /ID# 237278
    Cincinnati, Ohio 45212, United States
  • University of Cincinnati /ID# 234403
    Cincinnati, Ohio 45267, United States
  • Aventiv Research Columbus /ID# 236837
    Columbus, Ohio 43213, United States
  • OK Clinical Research /ID# 236675
    Edmond, Oklahoma 73034-3257, United States
  • IPS Research Company /ID# 237674
    Oklahoma City, Oklahoma 73106, United States
  • Summit Headlands LLC /ID# 236077
    Portland, Oregon 97210, United States
  • Abington Neurological Associates - Abington /ID# 236257
    Abington, Pennsylvania 19001, United States
  • Lehigh Center for Clinical Research /ID# 236703
    Allentown, Pennsylvania 18104-5034, United States
  • Suburban Research Associates - Media /ID# 236698
    Media, Pennsylvania 19063-1760, United States
  • Thomas Jefferson University Jefferson Headache Center /ID# 235821
    Philadelphia, Pennsylvania 19107, United States
  • Frontier Clinical Research /ID# 237924
    Smithfield, Pennsylvania 15478, United States
  • Clinical Trials of SC /ID# 237338
    Charleston, South Carolina 29406, United States
  • WR-ClinSearch /ID# 238287
    Chattanooga, Tennessee 37421-1605, United States
  • CNS Healthcare - Memphis /ID# 236396
    Memphis, Tennessee 38119, United States
  • FutureSearch Trials of Neurology /ID# 236428
    Austin, Texas 78731, United States
  • Tekton Research, Inc. /ID# 237306
    Austin, Texas 78745, United States
  • DiscoveResearch, Inc /ID# 236273
    Bryan, Texas 77802, United States
  • FutureSearch Trials of Dallas, LP /ID# 236276
    Dallas, Texas 75231, United States
  • Centex Studies, Inc. - Houston /ID# 237458
    Houston, Texas 77058, United States
  • ClinPoint Trials /ID# 236618
    Waxahachie, Texas 75165-1430, United States
  • Advanced Research Institute /ID# 237749
    Ogden, Utah 84403, United States
  • University of Utah /ID# 237602
    Salt Lake City, Utah 84112-5500, United States
  • Charlottesville Medical Research /ID# 237792
    Charlottesville, Virginia 22911, United States
  • Health Research of Hampton Roads, Inc. (HRHR) /ID# 237253
    Newport News, Virginia 23606, United States
  • Tidewater Integr Med Research /ID# 236867
    Virginia Beach, Virginia 23451, United States
  • Sentara Neurology Specialists - Virginia Beach /ID# 234350
    Virginia Beach, Virginia 23456-0019, United States
  • Northwest Clinical Research Center /ID# 237585
    Bellevue, Washington 98007, United States
  • Seattle Clinical Research Center /ID# 236912
    Seattle, Washington 98105, United States
  • Puget Sound Neurology /ID# 236322
    Tacoma, Washington 25328, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing, please refer to the link below

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Apr 2022, 19 months.

Results were first posted in May 2023, 1 year 1 month after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 19 months is close to that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2020
First posted
Jul 30, 2020
StartActual
Aug 21, 2020
Primary completionActual
Apr 19, 2022
CompletionActual
Apr 19, 2022
Results first posted
May 31, 2023
Last update
May 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04492020
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 30, 2020
Start date
Aug 21, 2020
Primary completion
Apr 19, 2022
Completion
Apr 19, 2022
Results posted
May 31, 2023
Last update
May 31, 2023

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ubrogepant

Start the discussion